Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States.
The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer.
The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications.
G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -0.10 Decreased by -171.43% | -0.16 Increased by +37.50% |
| May 1, 24 | -0.20 Increased by +62.26% | -0.21 Increased by +4.76% |
| Feb 28, 24 | -0.21 Increased by +71.23% | -0.28 Increased by +25.00% |
| Nov 1, 23 | -0.35 Increased by +40.68% | -0.33 Decreased by -6.06% |
| Aug 2, 23 | 0.14 Increased by +115.22% | -0.22 Increased by +163.64% |
| May 3, 23 | -0.53 Increased by +53.91% | -0.64 Increased by +17.19% |
| Mar 1, 23 | -0.73 Increased by +22.34% | -0.84 Increased by +13.10% |
| Nov 2, 22 | -0.59 Increased by +41.00% | -0.63 Increased by +6.35% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 16.55 M Decreased by -60.97% | -5.47 M Decreased by -162.79% | Decreased by -33.05% Decreased by -260.87% |
| Mar 31, 24 | 14.48 M Increased by +11.82% | -10.22 M Increased by +68.59% | Decreased by -70.59% Increased by +71.91% |
| Dec 31, 23 | 14.87 M Increased by +45.10% | -10.88 M Increased by +67.67% | Decreased by -73.14% Increased by +77.72% |
| Sep 30, 23 | 12.30 M Decreased by -47.83% | -18.20 M Increased by +27.97% | Decreased by -148.00% Decreased by -38.07% |
| Jun 30, 23 | 42.39 M Increased by +300.95% | 8.71 M Increased by +120.77% | Increased by +20.55% Increased by +105.18% |
| Mar 31, 23 | 12.95 M Increased by +87.57% | -32.53 M Increased by +36.96% | Decreased by -251.30% Increased by +66.39% |
| Dec 31, 22 | 10.25 M Increased by +76.85% | -33.65 M Increased by +15.92% | Decreased by -328.28% Increased by +52.46% |
| Sep 30, 22 | 23.58 M Increased by +385.30% | -25.27 M Increased by +40.49% | Decreased by -107.19% Increased by +87.74% |